Table 1

The recent string of successful phase III trials in SLE

TrialDrugPatientsPrimary outcome
TULIP 2AnifrolumabGeneral SLEBICLA (at 52 weeks)47.8% versus 31.5%
AURORAVoclosporinLupus nephritisRenal response (at 52 weeks)40.8% versus 22.5%
BLISS-LNBelimumabLupus nephritisPrimary efficacy renal response over 2 years43% versus 32%